

Marina P Siakantaris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4302929/publications.pdf>

Version: 2024-02-01

97
papers

1,783
citations

257101

24
h-index

301761

39
g-index

97
all docs

97
docs citations

97
times ranked

2017
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	0.6	5
2	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
3	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
4	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
5	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
6	Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. <i>Blood Cancer Journal</i> , 2020, 10, 116.	2.8	6
7	Validation of the simplified International Prognostic Score ³ in a Hellenic cohort of patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	1.2	4
8	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
9	Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature. <i>Hematological Oncology</i> , 2019, 37, 219-222.	0.8	4
10	Diagnostic role of cytology in serous effusions of patients with hematologic malignancies. <i>Diagnostic Cytopathology</i> , 2019, 47, 404-411.	0.5	11
11	Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 15-16.	0.9	20
12	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	1.3	3
13	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. <i>Blood</i> , 2018, 132, 666-670.	0.6	44
14	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon- β expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 2227-2239.	0.6	4
15	Prognostic indicators for mycosis fungoides in a Greek population. <i>British Journal of Dermatology</i> , 2017, 176, 1321-1330.	1.4	25
16	Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. <i>Anticancer Research</i> , 2017, 37, 2387-2391.	0.5	2
17	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
18	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	1.9	24

#	ARTICLE	IF	CITATIONS
19	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. <i>Leukemia</i> , 2016, 30, 238-242.	3.3	43
20	Cytomegalovirus Meningoencephalitis After Rituximab Treatment for Primary Central Nervous System Lymphoma. <i>Neurologist</i> , 2015, 19, 35-37.	0.4	8
21	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3230-3232.	0.6	1
22	Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, Tyr^{M1} and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	17
23	In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. <i>Experimental Dermatology</i> , 2014, 23, 931-933.	1.4	15
24	Systemic Mastocytosis Accompanied by a Non-Secretory Plasma Cell Dyscrasia and Nephrotic Syndrome-Level Proteinuria in a 76-Year-Old Patient. <i>Acta Haematologica</i> , 2014, 131, 78-83.	0.7	1
25	Survivin Messenger RNA Levels in Epstein-Barr Virus Positive Patients With Leukemic Low-Grade B-Cell Lymphomas Expressing the Latent Membrane Protein 1: Evidence of Apoptotic Function?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 56-60.	0.2	2
26	Composite Lymphomas: A Challenging Entity. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 80-89.	0.2	0
27	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 375-384.	0.6	20
28	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. <i>Oncologist</i> , 2013, 18, 190-197.	1.9	77
29	Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia. <i>Advances in Hematology</i> , 2013, 2013, 1-7.	0.6	7
30	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
31	Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience. <i>Transfusion and Apheresis Science</i> , 2012, 46, 189-193.	0.5	12
32	Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cll) Prognosis. <i>Blood</i> , 2012, 120, 4568-4568.	0.6	1
33	A Shorter Time to First Treatment and Worst Overall survival Is Observed in ClI Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays. <i>Blood</i> , 2012, 120, 4585-4585.	0.6	0
34	A Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides. <i>Blood</i> , 2012, 120, 2663-2663.	0.6	0
35	Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus. <i>Blood</i> , 2012, 120, 1560-1560.	0.6	0
36	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. <i>Leukemia and Lymphoma</i> , 2011, 52, 387-393.	0.6	35

#	ARTICLE	IF	CITATIONS
37	PUVA plus interferon $\hat{\pm}$ 2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 354-357.	1.3	27
38	Correlation of Fc Gamma RIIA Polymorphisms with EBV-Positivity and LMP1 Expression in Patients with Low Grade B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1600-1600.	0.6	12
39	Treatment of Splenic Marginal Zone Lymphoma with Rituximab Monotherapy in 59 Patients. <i>Blood</i> , 2011, 118, 2712-2712.	0.6	2
40	Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome. <i>Rheumatology International</i> , 2010, 30, 925-932.	1.5	11
41	Randomized Controlled Trials and Case Reports: Two Sides of the Same Coin?. <i>Research in Complementary Medicine</i> , 2009, 16, 195-195.	2.2	0
42	A chart review of patients with early-stage mycosis fungoides treated with psoralen plus ultraviolet A. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 218-219.	1.3	0
43	Early-stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. <i>Oncologist</i> , 2009, 14, 148-154.	1.9	13
44	CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.. <i>Blood</i> , 2009, 114, 2930-2930.	0.6	0
45	Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. <i>Anticancer Research</i> , 2009, 29, 1811-6.	0.5	11
46	Safety and Efficacy of Low-Dose Bexarotene and PUVA in the Treatment of Patients with Mycosis Fungoides. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 169-173.	3.3	34
47	Non-gastric extra-nodal marginal zone lymphomas—a single centre experience on 76 patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 2308-2315.	0.6	32
48	Topoisomerase III \pm Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1759-1766.	3.2	24
49	Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis. <i>Blood</i> , 2008, 112, 580-580.	0.6	3
50	Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. <i>Hematological Oncology</i> , 2007, 25, 127-131.	0.8	96
51	Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 240-243.	1.2	108
52	Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment. <i>Leukemia and Lymphoma</i> , 2006, 47, 557-560.	0.6	7
53	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. <i>European Journal of Haematology</i> , 2006, 77, 300-303.	1.1	47
54	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1657-1686.	1.0	12

#	ARTICLE	IF	CITATIONS
55	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. Blood, 2006, 108, 2745-2745.	0.6	4
56	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro.. Blood, 2006, 108, 4752-4752.	0.6	0
57	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. Blood, 2006, 108, 3522-3522.	0.6	0
58	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.. Blood, 2006, 108, 4655-4655.	0.6	0
59	Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN- α). The Importance of Maintenance.. Blood, 2006, 108, 4718-4718.	0.6	0
60	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood, 2005, 105, 1875-1880.	0.6	61
61	Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia, 2005, 19, 894-900.	3.3	59
62	Differential Diagnosis of Waldenström's Macroglobulinemia and Other B-Cell Disorders. Clinical Lymphoma and Myeloma, 2005, 5, 235-240.	2.1	31
63	Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. Blood, 2005, 106, 935-935.	0.6	4
64	Complex Patterns of Monoclonal Ig Diversification in B-CLL Cells from Different Tissue Compartments.. Blood, 2005, 106, 5021-5021.	0.6	0
65	Serum Levels of OPC and MIP-1 α in Untreated Multiple Myeloma Patients. Correlations with Staging, Survival and Bone Disease.. Blood, 2005, 106, 5074-5074.	0.6	0
66	Rituximab Monotherapy Is an Effective Treatment for Splenic Marginal Zone B-Cell Lymphomas (SMZL).. Blood, 2005, 106, 4800-4800.	0.6	0
67	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.. Blood, 2005, 106, 4785-4785.	0.6	0
68	Molecular Analysis of the VH Gene Usage in a Familial Case of Waldenström's Macroglobulinemia.. Blood, 2005, 106, 1005-1005.	0.6	0
69	Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.. Blood, 2005, 106, 5193-5193.	0.6	0
70	Serum Soluble Syndecan-1 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages.. Blood, 2005, 106, 3404-3404.	0.6	0
71	Thrombotic microangiopathy in a patient with Sezary syndrome treated with interferon- α . Nephrology Dialysis Transplantation, 2004, 19, 733-735.	0.4	8
72	Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. European Journal of Haematology, 2004, 72, 252-258.	1.1	27

#	ARTICLE	IF	CITATIONS
73	Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 765-781.	0.4	22
74	Adult T-Cell Leukemia/Lymphoma (ATLL): Report of Two Fully Documented Hellenic Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 715-721.	0.6	7
75	Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: Examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. <i>Oncology Reports</i> , 2004, 11, 899-903.	1.2	2
76	Serum Soluble Syndecan-1 Levels Correlate with Erythropoietin and Inversely with Hemoglobin Levels in Untreated Anaemic Myeloma Patients: Possible Role of Syndecan-1 in the Mechanisms of Chronic Anaemia.. <i>Blood</i> , 2004, 104, 4882-4882.	0.6	0
77	Lymphoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.. <i>Blood</i> , 2004, 104, 4595-4595.	0.6	0
78	B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstrom's Macroglobulinemia (MW): A Comparative Fish Analysis.. <i>Blood</i> , 2004, 104, 4801-4801.	0.6	0
79	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. <i>Seminars in Oncology</i> , 2003, 30, 201-205.	0.8	18
80	Pulmonary <i>Balantidium coli</i> infection in a leukemic patient. <i>American Journal of Hematology</i> , 2003, 73, 180-183.	2.0	67
81	A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. <i>British Journal of Haematology</i> , 2003, 122, 900-910.	1.2	17
82	A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 635-644.	0.6	9
83	Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. <i>European Journal of Haematology</i> , 2002, 68, 289-298.	1.1	8
84	B-chronic lymphocytic leukemia: practical aspects. <i>Hematological Oncology</i> , 2002, 20, 103-146.	0.8	41
85	The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. <i>Haematologica</i> , 2002, 87, 701-8; discussion 708.	1.7	34
86	Primary Lung Involvement in Waldenstrom's Macroglobulinaemia. <i>Acta Haematologica</i> , 2001, 105, 92-96.	0.7	33
87	Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody. <i>Blood</i> , 2001, 97, 2527-2528.	0.6	9
88	Imaging of Primary Central Nervous System Lymphoma before and after Radiotherapy. <i>The Neuroradiology Journal</i> , 2001, 14, 253-258.	0.1	0
89	Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients. <i>Annals of Hematology</i> , 2001, 80, 722-727.	0.8	86
90	Campath-1H (Anti-CD52) Monoclonal Antibody Therapy in Lymphoproliferative Disorders. <i>Medical Oncology</i> , 2001, 18, 99-108.	1.2	59

#	ARTICLE	IF	CITATIONS
91	Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. <i>European Journal of Haematology</i> , 2001, 67, 279-288.	1.1	29
92	Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period. <i>Medical Oncology</i> , 2000, 17, 70-73.	1.2	13
93	Primary Non-Hodgkin's Lymphoma of the Gall Bladder. <i>Leukemia and Lymphoma</i> , 2000, 40, 123-131.	0.6	32
94	Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response. <i>Leukemia and Lymphoma</i> , 2000, 40, 141-147.	0.6	23
95	EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2000, 37, 131-143.	0.6	16
96	Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia. <i>Clinical Biochemistry</i> , 1999, 32, 639-645.	0.8	19
97	Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. <i>British Journal of Haematology</i> , 1995, 89, 627-629.	1.2	36